Lyell Immunopharma Presentations At SITC Highlight New Nonclinical Data On Product Candidates And Innovative Technology To Shorten TIL Manufacturing
Portfolio Pulse from Benzinga Newsdesk
Lyell Immunopharma, Inc. (NASDAQ:LYEL) is presenting new nonclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The presentations include data on LYL119, its second generation ROR1-targeted CAR T cell product candidate, and its Epi-R P2 manufacturing process designed to shorten tumor infiltrating lymphocyte (TIL) manufacturing. The company also highlighted its collaboration with Outpace to enhance solid tumor T cell therapies and its rejuvenation technology to generate more stem-like T cells.
October 31, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lyell Immunopharma's presentations at SITC highlight its ongoing research and development efforts, which could potentially enhance its product pipeline and manufacturing processes. This could have a positive impact on the company's future growth prospects.
The company's presentations at SITC highlight its ongoing research and development efforts, including its LYL119 product candidate and its Epi-R P2 manufacturing process. These developments could potentially enhance the company's product pipeline and improve its manufacturing processes, which could have a positive impact on the company's future growth prospects.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100